Loading
Every dated change on the records linked to HR-positive / HER2-negative breast cancer, newest first: approvals and regulatory steps on its medicines, trials that reported, guideline versions, milestones, and when this page itself was checked. Dates come from the records; none is inferred. Orientation, not medical advice.
When this page itself was last checked or edited.
With imlunestrant, for ER-positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer
With abemaciclib, for ER-positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer
Risk stratification in early-stage HR+/HER2- invasive breast cancer
Genomic assay (Oncotype DX RS ≤25 node-negative or postmenopausal 1-3 nodes; MammaPrint low risk) → endocrine therapy alone; premenopausal RS 16-25 or high clinical risk → chemotherapy or OFS-based escalation. (NCCN 1)
PFS improved (HR not yet published in detail).
PFS 33.
A milestone in how this cancer is treated.
Weight loss achieved; primary iDFS endpoint not met at first analysis (presented 2025; publication pending, verify).
PFS HR 0.
Five-year invasive disease-free survival 91.
iDFS ~30% relative reduction (HR ~0.
Regional nodal irradiation after a complete nodal response to chemotherapy did not lengthen the invasive breast cancer recurrence-free interval (hazard ratio 0.
Implant loss 8.
PFS 16.
Ten-year overall survival 81.
PFS HR 0.
A milestone in how this cancer is treated.
PFS HR 0.
PFS HR 0.
Ongoing; the first block results and de-escalation rates were reported from 2024.
Palbociclib added to maintenance anti-HER2 and endocrine therapy lengthened progression-free survival.
PFS 6.
Five-year recurrence-free survival 89.
A milestone in how this cancer is treated.
First-line HR-positive, HER2-negative advanced breast cancer with an aromatase inhibitor (DAWNA-2)
Ten-year axillary recurrence 1.
PFS 15.
Residual cancer removed by guided margins in 27 of 357 patients; per-margin specificity 85.
5-year local recurrence 2.
Cancer detection 6.
iDFS HR 0.
5-year DFS 86.
One radiologist plus AI detected 261 screen-detected cancers vs 250 for two radiologists (relative proportion 1.
Five-year distant disease-free survival 98.
PFS HR 0.
A milestone in how this cancer is treated.
To decrease the incidence of febrile neutropenia in adults with non-myeloid malignancies receiving myelosuppressive chemotherapy
PFS HR 0.
OS HR 0.
OS 14.
A milestone in how this cancer is treated.
HR-positive, HER2-negative advanced breast cancer with fulvestrant after endocrine therapy (DAWNA-1)
PFS 15.
PFS HR 0.
iDFS HR 0.
One year of palbociclib added to endocrine therapy did not improve invasive disease-free survival.
A milestone in how this cancer is treated.
Detection of ER-positive lesions as an adjunct to biopsy in patients with recurrent or metastatic breast cancer
PFS 14.
At ten years, 28.
5-year ipsilateral breast tumour relapse 1.
iDFS HR 0.
PALLAS iDFS HR 0.
Circulating tumour DNA matched tissue genotyping with about 93 percent sensitivity; neratinib (HER2 mutations) and capivasertib plus fulvestrant (AKT1 mutations, receptor-positive) met their response thresholds; extended-dose fulvestrant for ESR1 mutations did not.
No chemo benefit postmenopausal; iDFS HR 0.
Five-year local recurrence 2.
A milestone in how this cancer is treated.
Within three months of immediate implant-based reconstruction: implant loss 9 percent, infection needing treatment 25 percent, return to theatre 18 percent and readmission 18 percent, all above the National Quality Standards.
10-year ipsilateral breast tumour recurrence 4.
Eight-year ipsilateral breast tumour recurrence 3.
5-year OS 42.
A milestone in how this cancer is treated.
PFS 8.
Ten-year disease-free survival 76.
At two years, autologous reconstruction gave higher satisfaction with breasts (7.
PFS 11.
9-year iDFS 83.
A milestone in how this cancer is treated.
First-line HR+ advanced breast cancer (FALCON)
Ten-year overall survival 86.
5-year DFS 74.
5-year local relapse 0.
PFS HR 0.
PFS 7.
Multiple graduations (veliparib-carboplatin, neratinib, pembrolizumab, MK-2206, T-DM1 plus pertuzumab, durvalumab plus olaparib, cemiplimab plus fianlimab); pembrolizumab's graduation preceded its approval in early triple-negative breast cancer.
5-year distant metastasis-free survival 94.
OS 63.
PFS HR 0.
Adding the clipped node to sentinel node dissection cut the false-negative rate from 10.
Twenty-year ipsilateral breast recurrence 12.
10-year overall survival 82.
10-year disease-free survival 82.
10-year local recurrence 9.
A milestone in how this cancer is treated.
Prognosis of distant recurrence in postmenopausal HR+ early breast cancer (510(k))
False-negative rate of sentinel node surgery after chemotherapy 12.
Ten-year local-regional relapse 6.
CE-IVD
Everolimus plus exemestane more than doubled progression-free survival compared with exemestane alone; approved in July 2012.
At a median 22.
First targeted agent to overcome endocrine resistance.
HR+ advanced breast cancer after antioestrogen therapy
Twenty-year same-breast recurrence 8.
No significant difference in disease-free, relapse-free, distant-disease-free or overall survival between radical mastectomy, total mastectomy with irradiation and total mastectomy alone, at twenty-five years.
Twenty-year recurrence in the treated breast 14.
A milestone in how this cancer is treated.
Treatment and prevention of postmenopausal osteoporosis
Metastatic breast cancer in postmenopausal women with ER-positive or unknown tumours
82b: 10-year locoregional recurrence 9% vs 32%; overall survival 54% vs 45%.
Tumour-induced hypercalcaemia; prevention of skeletal events in breast cancer with bone metastases (Bondronat)
First-line hormonal treatment of hormone-dependent metastatic breast cancer in postmenopausal women